
Operations Office

Telephone (507) 266-3853



Date: June 25, 2009

To: NCCTG Primary CRAs, Primary PIs

From: Linda S. Long
Research Protocol Specialist III

Re: N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

This memo is to notify NCCTG sites that patients cannot be enrolled to this study until the local IRB has approved Addendum 1 to the protocol. Sorafenib is not being supplied by Bayer as stated in the current consent form (see memo dated May 12, 2009). The consent form is corrected with Addendum 1. Also, attached is an updated eligibility checklist to reflect that IRB approval of Addendum 1 is required.

If you have any questions concerning this communication, please contact me at 507/266-3853.